Trial Profile

Compassionate Use Access to REP 2139-Mg for the Treatment of Chronic HBV Infection or Chronic HBV / HDV Co-infection

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REP 2139 (Primary) ; REP 2139 (Primary) ; Peginterferon alfa-2a; Tenofovir disoproxil fumarate
Indications Hepatitis B; Hepatitis D
Focus Adverse reactions; Expanded access; Therapeutic Use
Acronyms RCAP
Sponsors REPLICor

17 Feb 2025 Status changed from recruiting to completed.
14 Nov 2023 Results assessing safety and efficacy of REP 2139-Mg in CHD patients with decompensated cirrhosis were presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
14 Nov 2023 Results (N=11) assessing safety and efficacy of of weekly SC injection of REP 2139-Mg in combination therapy were presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com